New Horizon Medical Solutions

What New Horizon Medical Solutions does

New Horizon Medical Solutions is a privately held LLC headquartered in Las Vegas, Nevada, that operates as an integrated wound care platform serving hospitals, wound care centers, podiatry groups, and surgical practices across all 50 US states. The company distributes an amniotic membrane-based skin substitute portfolio (AdvoGraft One, AdvoGraft Membrane Dual, AmnioBand Membrane, Xcell Amnio Matrix, Xcellerate, AmchoPlast, Xceed TL Matrix), diagnostic imaging devices (SnapshotNIR for near-infrared tissue oxygenation and SnapshotGLO for bacterial autofluorescence) under exclusive US distribution from Kent Imaging, advanced hardware modalities including the Platform Wound Dressing transparent negative pressure wound therapy system, the Xpansion micro-autografting kit, Söring ultrasonic-assisted debridement instruments, and the Aurix platelet-rich plasma system.

The company's products span the full wound care continuum from assessment through debridement, negative pressure therapy, biologics, and autologous closure, supported by an affiliated New Horizon Billing Solutions entity that provides revenue cycle management, audit defense, and provider compliance services. NHMS generates revenue through per-unit and per-square-centimeter pricing on biologics reimbursed via HCPCS Level II codes, hardware sales of capital equipment and consumables, and professional services through the billing affiliate. The firm employs an enterprise field sales motion targeting healthcare providers nationwide and operates an additional channel through distribution partners, complemented by clinical education delivered through the New Horizon Institute facility in Las Vegas.

NHMS is transitioning from a distribution-led model to a vertically integrated manufacturer, having acquired Precise Bioscience (lyophilized amniotic membrane technology) in December 2024 and Applied Tissue Technologies (NPWT and micro-autografting IP) in December 2025, and having broken ground on the Precision Biologics Manufacturing GMP facility in Southern Nevada in September 2025, which is expected to begin operations in the second half of 2026 with 200-300 new jobs. The leadership team is composed of veterans of KCI/3M, Smith & Nephew, Pfizer, Allergan, Stryker, ConvaTec, and other large medtech companies, and a seven-member Medical Advisory Board co-led by Drs. Tharesh Udupa and Robert T. Grant supports clinical strategy. The platform composition spans five modalities: diagnostic imaging, ultrasonic debridement, NPWT, advanced skin substitutes, and micro-autografting, marketed as a single-partner alternative to fragmented multi-vendor relationships for wound care practices.

Name

New Horizon Medical Solutions

Legal name

New Horizon Medical Solutions LLC

Website

https://nhmedical.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

New Horizon Medical Solutions is a Las Vegas-based wound care platform that distributes and manufactures skin substitutes, diagnostic imaging, NPWT, ultrasonic debridement, micro-autografting, and PRP products, serving hospitals, wound care centers, podiatry groups, and surgical practices across all 50 US states.

Ownership category

akta.pro rank

Product category

Advanced Wound Care

NAICS

Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Services-Health Services (8000)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Wound Care & Ulcer Management (HLAKACAN), Wound Care & Diabetic Foot Infection (HLAKAGAK)

Keywords

• Advanced wound care
• Skin substitutes
• Biologic allografts
• Negative pressure therapy
• Wound diagnostics

Headquarters

HQ city

Las Vegas

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure, Technology or R&D

Revenue model

1. Skin Substitutes and Biologics Sales: Sale of amniotic membrane allografts (AdvoGraft One, AdvoGraft Membrane Dual, Xcell Amnio Matrix, Xcellerate, AmnioBand, AmchoPlast) for wound care applications. Products are sold to healthcare providers including hospitals, wound care centers, and surgical practices.
2. Medical Device Sales: Sale of diagnostic imaging devices (SnapshotNIR, SnapshotGLO), NPWT systems (Platform Wound Dressing), debridement instruments (Söring UAW), micro-autografting kits (Xpansion), and PRP systems (Aurix) to healthcare providers.
3. Reimbursement and Billing Services: Support services provided through affiliate company New Horizon Billing Solutions for revenue cycle management, audit defense, and provider compliance programs.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

New Horizon Medical Solutions operates an integrated wound care platform that supplies skin substitute biologics (amniotic membrane allografts), diagnostic imaging devices, negative pressure wound therapy systems, micro-autografting kits, ultrasonic debridement instruments, and platelet-rich plasma systems to healthcare providers. The company also offers reimbursement support and billing/managed services through its affiliate New Horizon Billing Solutions.

Product overview

New Horizon Medical Solutions operates as an integrated wound care platform combining multiple product categories across the full wound care continuum. The platform includes diagnostic imaging devices (SnapshotNIR, SnapshotGLO), skin substitutes/biologics (AdvoGraft One, AdvoGraft Membrane Dual, AmnioBand Membrane, Xcell Amnio Matrix, Xcellerate, AmchoPlast), negative pressure wound therapy (Platform Wound Dressing), micro-autografting (Xpansion Kit), ultrasonic debridement (Soring UAW), and PRP therapy (Aurix System). The company also provides reimbursement support through affiliated New Horizon Billing Solutions, positioning itself as a comprehensive wound care partner offering products, education, logistics, and billing support.

Differentiator

Problem solved

Functional benefit

Products and services

• AdvoGraft One Dehydrated, single-layer amniotic membrane allograft derived from human placental tissue for acute and chronic wound settings. Provides barrier protection with retained extracellular matrix that augments cell migration and adhesion, sold to healthcare providers under HCPCS Q4380.
• AdvoGraft Membrane Dual Dehydrated, dual-layer placental allograft combining amniotic and chorionic membranes for structural integrity in deep or complex wounds. Packaged sterile and ambient stable, sold under HCPCS Q4382.
• AmnioBand Membrane Minimally processed human bi-layer placental allograft (amnion and chorion) retaining extracellular matrix structural properties. Used as wound covering for native tissue restoration and remodeling, sold under HCPCS Q4151.
• Xcell Amnio Matrix (XAM) Next-generation lyophilized amniotic membrane allograft combining barrier protection, structural support, and handling simplicity. Features dual-sided application requiring no orientation during placement.
• Xcellerate Advanced amniotic membrane allograft with extracellular matrix for robust wound coverage. Designed for wounds requiring enhanced structural integrity and support, sold under HCPCS Q4234.
• AmchoPlast Sterile, minimally manipulated, dehydrated allograft derived from human placental membranes (amnion, intermediate layer, and chorion). Tri-layer construction provides enhanced handling and slower degradation, sold under HCPCS Q4316.
• Xceed TL Matrix Tri-layer placental-derived allograft designed to enhance wound management with consistency, advanced material composition, strength, extracellular matrix incorporation, and reliability.
• SnapshotNIR FDA-cleared portable, non-contact near-infrared imaging device that maps oxygenated and deoxygenated hemoglobin to visualize tissue oxygen saturation (StO2) at point of care, with no dyes, injections, or patient contact required.
• SnapshotGLO FDA 510(k) cleared handheld imaging device using ultraviolet light to visualize areas of elevated bacterial load on wound surfaces via autofluorescent bacterial signatures.
• Platform Wound Dressing (PWD) Advanced transparent negative pressure wound therapy dressing with a proprietary embossed structure that evenly distributes negative pressure across the wound surface at pressures as low as -50 mmHg without foam or gauze.
• Xpansion Micro-Autografting Kit Sterile, single-use system that transforms small donor skin samples into evenly sized micro-autografts using mechanical mincing, maximizing wound coverage while minimizing donor site size and morbidity.
• Söring UAW (Ultrasonic-Assisted Wound Debridement) Ultrasonic-assisted wound debridement system using 25 kHz ultrasonic cavitation to disrupt biofilm and remove devitalized tissue while preserving surrounding tissue. Includes Double-Ball, Hoof, and Spatula sonotrodes.
• Aurix System (PRP) Point-of-care platelet-rich plasma system for rapid preparation of autologous PRP gel from patient blood. Features a proprietary 1-minute spin protocol with a 96.5% positive response rate in chronic wounds; gel ready to apply in 5-8 minutes after blood draw.
• Reimbursement Support and Billing Services Support services delivered through affiliated New Horizon Billing Solutions, including revenue cycle management, audit defense, claims support, documentation workflow support, and provider compliance programs for NHMS customers.

Quantifiable outcome

• 96.5% positive response rate in all types of chronic wounds for Aurix PRP System
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core.

• Applied Tissue Technologies (ATT)coreOEM/ Whitelabel/ Licensing Partner · 29 December 2025Acquisition of Applied Tissue Technologies' business assets, including transparent negative pressure wound therapy device (Platform Wound Dressing) and micro-grafting kit (Xpansion). ATT is a 25-year-old wound care company based in Boston, Massachusetts, founded by Dr. Elof Eriksson, former chief of plastic and reconstructive surgery at Brigham and Women's Hospital and holder of the Joseph E. Murray chair at Harvard Medical School. Products are designed for use in established economic zones and underserved areas.
• Kent ImagingcoreChannel Partner/ Reseller/ Distributor · 2 December 2025Exclusive US distribution partnership granting New Horizon Medical Solutions sole authority to market, promote, and distribute Kent Imaging's complete portfolio including SnapshotNIR (near-infrared tissue oxygenation imaging) and SnapshotGLO (bacterial autofluorescence imaging) across all 48 contiguous states. Kent Imaging is a Calgary-based pioneer in near-infrared spectroscopy medical imaging, celebrating 20 years of innovation since founding in 2006.
• Precise BiosciencecoreOEM/ Whitelabel/ Licensing Partner · 29 December 2024Acquisition of Precise Bioscience, a leader in advanced lyophilized amniotic membrane technology-based products. The portfolio includes Xcell Amnio Matrix (XAM) family and Xcellerate, advanced lyophilized amniotic membrane products featuring proprietary processing that preserves the extracellular matrix and growth factors. Precise Bioscience is now a wholly-owned subsidiary of New Horizon Medical Solutions.
• New Horizon Billing SolutionscoreStrategic or Co-development PartnerAffiliate company providing dedicated billing and reimbursement support services including revenue cycle management, audit defense, claims support, documentation workflow support, and provider compliance programs. Operates as a separate entity under common ownership to support NHMS customers.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Others

• Kent Imaging: Kent Imaging manufactures the SnapshotNIR and SnapshotGLO devices that NHMS distributes exclusively in the US; included as an ecosystem partner whose product strategy directly shapes NHMS's imaging modality.

Broad incumbents

• ConvaTec: ConvaTec offers an advanced wound care portfolio including AQUACEL dressings and biologic skin substitutes, serving similar hospitals, wound care centers, and home health providers as NHMS.
• 3M Health Care (Solventum): 3M/Solventum's KCI legacy business is the market leader in negative pressure wound therapy (V.A.C. therapy), directly competing with NHMS's Platform Wound Dressing across hospital and wound care center accounts.
• Coloplast: Coloplast's Wound & Skin Care division provides advanced dressings and skin substitutes to hospitals and specialty wound clinics, competing with NHMS across multiple product categories.
• Smith & Nephew: Smith & Nephew's Advanced Wound Management portfolio spans skin substitutes, NPWT (PICO), and traditional dressings — a broad incumbent competing across multiple NHMS modalities at scale.
• Integra LifeSciences: Integra LifeSciences offers regenerative skin substitutes (Integra Dermal Regeneration Template) and a broad wound care portfolio, overlapping with NHMS's biologics and surgical wound care offerings.

Direct peers

• Organogenesis Holdings: Organogenesis is a leading regenerative medicine company selling skin substitutes (Apligraf, Dermagraft, Puraply) and wound care biologics into hospitals, wound care centers, and podiatry groups — the same customer base NHMS targets with its amniotic membrane portfolio.
• MiMedx Group: MiMedx sells dehydrated amniotic membrane allografts (EpiFix, AmnioFix, AmnioCord) directly to wound care and surgical providers, directly competing with NHMS's AdvoGraft, AmnioBand, Xcell, and AmchoPlast products.

Emerging players

• Vericel: Vericel markets autologous cell therapies for wound and cartilage repair (e.g., MACI, NexoBrid), a smaller but direct competitor in the regenerative advanced wound therapy category where NHMS's Xpansion and Aurix compete.
• PolarityBio: PolarityBio develops regenerative skin and wound care biologics and has overlapping leadership pedigree (Raymond Jessen's previous employer), competing in similar hospital and wound care channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php?id=61574814663498
• LinkedInlinkedin.com/company/91391892/admin/dashboard
• Instagraminstagram.com/newhorizonmedical

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about New Horizon Medical Solutions